Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (61-70 of 133) with videos related to

Pageof 14
Sort By:
Circulation|September 24, 2013
Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertensionEkkehard Grünig, Henning Tiede, Esi Otuwa Enyimayew, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trialJulia Mascherbauer, Ekkehard Grünig, Michael Halank, et al.
Lung|May 18, 2013
Exercise capacity affects quality of life in patients with pulmonary hypertensionMichael Halank, Franziska Einsle, Stephanie Lehman, et al.
European Heart Journal|May 13, 2005
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertensionChristian F Opitz, Roland Wensel, Jörg Winkler, et al.
Pulmonary Circulation|August 23, 2023
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinilPavel Jansa, Grzegorz Kopeć, Adam Torbicki, et al.
Pneumologie (Stuttgart, Germany)|November 14, 2023
[Medication treatment in pulmonary arterial hypertension with comorbidities - Which phenotypes and points to consider]Ekkehard Grünig, Michael Halank, Claus Neurohr, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[Chronic Thromboembolic Pulmonary Hypertension]Christoph B Wiedenroth, Olympia Bikou, Simone von Bonin, et al.
Pneumologie (Stuttgart, Germany)|November 14, 2023
[Pulmonary hypertension associated with lung disease]Michael Halank, Katarina E Zeder, Natascha Sommer, et al.
International Journal of Cardiology|May 27, 2015
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionAlberto M Marra, Benjamin Egenlauf, Nicola Ehlken, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 26, 2018
The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registryThomas A Zelniker, Dörte Huscher, Anton Vonk-Noordegraaf, et al.
Pageof 14

Showing results (61-70 of 133) with videos related to

Sort By:
Pageof 14
Circulation|September 24, 2013
Assessment and prognostic relevance of right ventricular contractile reserve in patients with severe pulmonary hypertensionEkkehard Grünig, Henning Tiede, Esi Otuwa Enyimayew, et al.
Wiener Klinische Wochenschrift|September 4, 2016
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trialJulia Mascherbauer, Ekkehard Grünig, Michael Halank, et al.
Lung|May 18, 2013
Exercise capacity affects quality of life in patients with pulmonary hypertensionMichael Halank, Franziska Einsle, Stephanie Lehman, et al.
European Heart Journal|May 13, 2005
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertensionChristian F Opitz, Roland Wensel, Jörg Winkler, et al.
Pulmonary Circulation|August 23, 2023
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinilPavel Jansa, Grzegorz Kopeć, Adam Torbicki, et al.
Pneumologie (Stuttgart, Germany)|November 14, 2023
[Medication treatment in pulmonary arterial hypertension with comorbidities - Which phenotypes and points to consider]Ekkehard Grünig, Michael Halank, Claus Neurohr, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[Chronic Thromboembolic Pulmonary Hypertension]Christoph B Wiedenroth, Olympia Bikou, Simone von Bonin, et al.
Pneumologie (Stuttgart, Germany)|November 14, 2023
[Pulmonary hypertension associated with lung disease]Michael Halank, Katarina E Zeder, Natascha Sommer, et al.
International Journal of Cardiology|May 27, 2015
Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertensionAlberto M Marra, Benjamin Egenlauf, Nicola Ehlken, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 26, 2018
The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registryThomas A Zelniker, Dörte Huscher, Anton Vonk-Noordegraaf, et al.
Pageof 14